CymaBay Announces the Appointments of Robert Booth and Caroline Loewy to Its Board of Directors Pharmaceutical Investing
UCB and Dermira Announce Second CIMZIA® Phase 3 Trial Meets Co-Primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis Pharmaceutical Investing
Horizon Pharma Announces Topline Results from Phase 3 Study of ACTIMMUNE in Friedreich's Ataxia Pharmaceutical Investing
Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study Life Science Investing
Ohr Pharmaceutical Announces Pricing of $7.75 Million Public Offering of Common Stock and Warrants Life Science Investing
Catalyst Pharmaceuticals Provides Update on Clinical Trial for Patients with Congenital Myasthenic Syndromes Pharmaceutical Investing
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Drug Candidate for Ulcerative Colitis Pharmaceutical Investing
CymaBay Therapeutics Announces the Initiation of Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis Pharmaceutical Investing
Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001 for the Treatment of Alopecia Totalis and Alopecia Universalis Life Science Investing
